Characterization of binding sites of a new neurotensin receptor antagonist, [3H]SR 142948A, in the rat brain

European Journal of Pharmacology

Volumn 343, Issue 1, 1998, Pages 67-77

  Betancur, Catalina ^a   Canton, Maryse ^b   Burgos, Alain ^b   Labeeuw, Bernard ^b   Gully, Danielle ^b   Rostène, William ^a   Pélaprat, Didier ^a  

^a HÔPITAL SAINT ANTOINE   (France)

^b SANOFI   (France)

Author keywords

3H SR 142948A; Brain; Levocabastine; Neurotensin receptor; Nonpeptide receptor antagonist; Receptor autoradiography

Indexed keywords

2 [5 (2,6 DIMETHOXYPHENYL) 1 [4 [N (3 DIMETHYLAMINOPROPYL) N METHYLCARBAMOYL] 2 ISOPROPYLPHENYL] 1H PYRAZOL 3 YLCARBONYLAMINO]ADAMANTANE 2 CARBOXYLIC ACID; 2 [[1 (7 CHLORO 4 QUINOLINYL) 5 (2,6 DIMETHOXYPHENYL) 3 PYRAZOLYL]CARBONYLAMINO] 2 ADAMANTANECARBOXYLIC ACID; GUANINE NUCLEOTIDE; LEVOCABASTINE; NEUROTENSIN; NEUROTENSIN RECEPTOR; NEUROTENSIN RECEPTOR ANTAGONIST; UNCLASSIFIED DRUG;

ANIMAL TISSUE; ARTICLE; AUTORADIOGRAPHY; BINDING COMPETITION; BINDING KINETICS; BRAIN; BRAIN HOMOGENATE; CONTROLLED STUDY; DENSITOMETRY; DRUG BINDING SITE; DRUG RECEPTOR BINDING; MALE; NONHUMAN; PRIORITY JOURNAL; RAT;

ADAMANTANE; ANIMALS; AUTORADIOGRAPHY; BINDING SITES; BRAIN; IMIDAZOLES; MALE; PIPERIDINES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, NEUROTENSIN; TRITIUM;

EID: 0032484994     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-2999(97)01510-0     Document Type: Article

References (43)

1. 3H]SR 48692, in the guinea pig brain J. Pharmacol. Exp. Ther. 273:1995;1450-1458.
2. Betancur C., Azzi M., Rostène W. Nonpeptide antagonists of neuropeptide receptors: Tools for research and therapy. Trends Pharmacol. Sci. 18:1997;372-386.
3. Chalon P., Vita N., Kaghad M., Guillemot M., Bonnin J., Delpech B., Le Fur G., Ferrara P., Caput D. Molecular cloning of a levocabastine-sensitive neurotensin binding site. FEBS Lett. 386:1996;91-94.
4. 3H]-(±)-L-364,718: A new potent, nonpeptide cholecystokinin antagonist radioligand selective for peripheral receptors Mol. Pharmacol. 30:1986;212-217.
5. 3H]L-365,260: A new potent and selective brain cholecystokinin (CCK-B) and gastrin receptor antagonist radioligand Mol. Pharmacol. 35:1989;803-808.
6. 50) of an enzymatic reaction. Biochem. Pharmacol. 22:1973;3099-3108.
7. Chung F.Z., Wang C.D., Potter P.C., Venter J.C., Fraser C.M. Site-directed mutagenesis and continuous expression of human β-adrenergic receptors. J. Biol. Chem. 263:1988;4052-4055.
8. Dubuc I., Costentin J., Terranova J.P., Barnouin M.C., Soubrié P., Le Fur G., Rostène W., Kitabgi P. The nonpeptide neurotensin antagonist, SR 48692, used as a tool to reveal putative neurotensin receptor subtypes. Br. J. Pharmacol. 112:1994;352-354.
9. Emson P.C., Goedert M., Horsfield P.M., Rioux F., St. Pierre S. The regional distribution and chromatographic characterization of neurotensin-like immunoreactivity in the rat central nervous system. J. Neurochem. 38:1982;992-999.
10. Gaudriault G., Zsürger N., Vincent J.P. Radiolabeled ligands specific for the G protein-coupled state of neurotensin receptors. J. Neurochem. 67:1996;2590-2598.
11. Goedert M., Pittaway K., Williams B.J., Emson P.C. Specific binding of tritiated neurotensin to rat brain membranes: Characterization and regional distribution. Brain Res. 304:1984;71-81.
12. Gully D., Canton M., Boigegrain R., Jeanjean F., Molimard J.C., Poncelet M., Gueudet C., Heaulme M., Leyris R., Brouard A., Pélaprat D., Labbé-Jullié C., Mazella J., Soubrié P., Maffrand J.P., Rostène W., Kitabgi P., Le Fur G. Biochemical and pharmacological profile of a potent and selective nonpeptide antagonist of neurotensin receptor. Proc. Natl. Acad. Sci. USA. 90:1993;65-69.
13. Gully D., Labeeuw B., Boigegrain R., Oury-Donat F., Bachy A., Poncelet M., Steinberg R., Suaud-Chagny M.F., Santucci V., Vita N., Pecceu F., Labbé-Jullié C., Kitabgi P., Soubrié P., Le Fur G., Maffrand J.P. Biochemical and pharmacological activities of SR 142948A, a new potent neurotensin receptor antagonist. J. Pharmacol. Exp. Ther. 280:1997;802-812.
14. Hermans E., Octave J.N., Maloteaux J.M. Interaction of the COOH-terminal domain of the neurotensin receptor with a G protein does not control the phospholipase C activation but is involved in the agonist-induced internalization. Mol. Pharmacol. 49:1996;365-372.
15. Kasckow J., Nemeroff C.B. The neurobiology of neurotensin: Focus on neurotensin-dopamine interactions. Regul. Pept. 36:1991;153-164.
16. Kitabgi P., Rostène W., Dussaillant M., Schotte A., Laduron P.M., Vincent J.P. Two populations of neurotensin binding sites in murine brain: Discrimination by the antihistamine levocabastine reveals markedly different radioautographic distribution. Eur. J. Pharmacol. 140:1987;285-293.
17. 3H]SR 48692, the first nonpeptide neurotensin antagonist radioligand: Characterization of binding properties and evidence for distinct agonist and antagonist binding domains on the rat neurotensin receptor Mol. Pharmacol. 47:1995;1050-1056.
18. Le F., Cusak B., Richelson E. The neurotensin receptor: Is there more than one subtype? Trends Pharmacol. Sci. 17:1996;1-3.
19. Maeda S., Lameh J., Mallet W.G., Philip M., Ramachandran J., Sadée W. Internalization of the Hm1 muscarinic cholinergic receptor involves the third cytoplasmic loop. FEBS Lett. 269:1990;386-388.
20. Mai J., Triepel K.J., Metz J. Neurotensin in the human brain. Neuroscience. 22:1987;499-524.
21. 11-neurotensin, a highly radioactive ligand of neurotensin receptors: Preparation, biological activity, and binding properties to rat brain synaptic membranes. J. Biol. Chem. 258:1983;3476-3481.
22. Mazella J., Botto J.M., Guillemare E., Coppola T., Sarret P., Vincent J.P. Structure, functional expression, and cerebral localization of the levocabastine-sensitive neurotensin/neuromedin N receptor from mouse brain. J. Neurosci. 16:1996;5613-5620.
23. 1) receptor antagonist. Science. 251:1991;437-439.
24. 3-neurotensin Neuroscience. 22:1987;525-536.
25. Munson P.J., Rodbard D. LIGAND: A versatile computerized approach for characterization of ligand-binding systems. Anal. Biochem. 107:1980;220-239.
26. Nicot A., Rostène W., Bérod A. Neurotensin receptor expression in the rat forebrain and midbrain: A combined analysis by in situ hybridization and receptor autoradiography. J. Comp. Neurol. 341:1994;407-419.
27. Paxinos, G., Watson, C., 1986. The Rat Brain in Stereotaxic Coordinates, 2nd ed. Academic Press, Sydney.
28. Pugsley T.A., Akunne H.C., Whetzel S.Z., Demattos S., Corbin A.E., Wiley J.N., Wustrow D.J., Wise L.D., Heffner T.G. Differential effects of the nonpeptide neurotensin antagonist, SR 48692, on the pharmacological effects of neurotensin agonists. Peptides. 16:1995;37-44.
29. Rosenkilde M.M., Cahir M., Gether U., Hjorth S.A., Schwartz T.W. Mutations along transmembrane segment II of the NK-1 receptor affect substance P competition with non-peptide antagonists but not substance P binding. J. Biol. Chem. 269:1994;28160-28164.
30. Rostène W.H., Alexander M.J. Neurotensin and neuroendocrine regulation. Front. Neuroendocrinol. 18:1997;115.
31. Sadoul J.L., Mazella J., Amar S., Kitabgi P., Vincent J.P. Preparation of neurotensin selectively iodinated on the tyrosine 3 residue. Biological activity and binding properties on mammalian neurotensin receptors. Biochem. Biophys. Res. Commun. 120:1984;812-819.
32. 3H]neurotensin binding site in rat brain Naunyn Schmiedebergs Arch. Pharmacol. 333:1986;400-405.
33. Schotte A., Rostène W., Laduron P.M. Different subcellular localization of neurotensin receptor and neurotensin acceptor sites in the rat brain dopaminergic system. J. Neurochem. 50:1988;1026-1031.
34. Schwartz T.W., Gether U., Schambye H.T., Hjorth S.A. Molecular mechanism of action of nonpeptide ligands for peptide receptors. Curr. Pharm. Design. 1:1995;355-372.
35. Steinberg R., Brun P., Fournier M., Souilhac J., Rodier D., Mons G., Terranova J.P., Le Fur G., Soubrié P. SR 48692, a non-peptide neurotensin receptor antagonist differentially affects neurotensin-induced behaviour and changes in dopaminergic transmission. Neuroscience. 59:1994;921-929.
36. 1-antihistamine activity. Drug Dev. Res. 8:1986;87-93.
37. Talkad V.D., Fortune K.P., Pollo D.A., Shah G.N., Wank S.A., Gardner J.D. Direct demonstration of three different states of the pancreatic cholecystokinin receptor. Proc. Natl. Acad. Sci. USA. 91:1994;1868-1872.
38. Tanaka K., Masu M., Nakanishi S. Structure and functional expression of the cloned rat neurotensin receptor. Neuron. 4:1990;847-854.
39. 2 receptor subtypes Mol. Pharmacol. 38:1990;594-598.
40. Vincent J.P. Neurotensin receptors: Binding properties, transduction pathways and structure. Cell. Mol. Neurobiol. 15:1995;501-512.
41. Vita N., Laurent P., Leport S., Chalon P., Dumont X., Kaghad M., Gully D., Le Fur G., Ferrara P., Caput D. Cloning and expression of a complementary DNA encoding a high affinity human neurotensin receptor. FEBS Lett. 317:1993;139-142.
42. Waelbroeck M., Robberecht P., Chatelain P., Christophe J. Rat cardiac muscarinic receptors. I. Effects of guanine nucleotides on high- and low-affinity binding sites. Mol. Pharmacol. 21:1982;581-588.
43. Yamada M., Yamada M., Watson M.A., Richelson E. Deletion of the putative third intracellular loop of the rat neurotensin receptor abolishes phosphoinositide hydrolysis but not cyclic AMP formation in CHO-K1 cells. Mol. Pharmacol. 46:1994;470-476.